Stories by Linda A. Johnson

Monday, June 6, 2016

Patients in poor countries struggle despite low prices

TRENTON, N.J. - Cancer drugs predictably cost much more in the U.S. than in poor countries and even other wealthy nations, but a study shows they are less affordable in some developing countries ...
By Linda A. Johnson

Monday, May 16, 2016

Pfizer buying skin drug maker Anacor for $5.2 billion

TRENTON, N.J. - Pfizer is fortifying its key immunology and inflammation drug business, snapping up a small maker of skin disorder treatments for about $5.2 billion, weeks after the U.S.
By Linda A. Johnson

Friday, April 29, 2016

Valeant files overdue financial report, ending debt default

Valeant Pharmaceuticals resolved its default on some of its $30 billion in debt by finally filing its long-overdue U.S. financial report for 2015 on Friday. The badly tarnished Canadian drugmaker ...
By Linda A. Johnson

Wednesday, April 6, 2016

$150 billion deal off Allergan, Pfizer say

Top U.S. drugmaker Pfizer and Irish rival Allergan are charting independent futures after scrapping a record $160 billion deal torpedoed by new Treasury Department rules.
By Linda A. Johnson

Tuesday, April 5, 2016

New inversion rules will kill Pfizer-Allergan deal

Drugmakers Pfizer Inc. and Allergan Plc are scrambling to determine whether to proceed with a plan to merge and move Pfizer's address - but not its operations or headquarters - to lower-tax ...
By Linda A. Johnson

Friday, March 25, 2016

Jury orders Gilead to pay $200 million to Merck

The federal jury in a high-stakes patent trial ordered drugmaker Gilead to pay rival Merck $200 million in damages for infringing on patents for hepatitis C drugs.
By Linda A. Johnson

Tuesday, March 15, 2016

Troubled drugmaker cuts forecasts

Shares of Valeant Pharmaceu­ticals crashed Tuesday after the embattled drugmaker failed to reassure investors that it's getting back on track and conceded for the first time that it's technically ...
By Linda A. Johnson

Monday, Feb. 29, 2016

Drugmaker Valeant reveals SEC inquiry

Valeant Pharmaceuticals is entangled in an SEC investigation that compounds the drugmaker's headaches as it grapples with questions about its pricing practices, finances and CEO's health.
By Linda A. Johnson

Monday, Jan. 11, 2016

Drugmaker Shire to acquire Baxalta

Irish drugmaker Shire PLC's second attempt to buy Baxalta looks more likely to succeed, with Baxalta's board backing the sweetened offer of $32 billion in cash and stock. If the deal goes through, ...
By Linda A. Johnson

Monday, Dec. 28, 2015

Amazon says its holiday shipping, Christmas Eve deliveries set records

TRENTON, N.J. - Online retailer Amazon has been a prime beneficiary of more consumers doing their holiday shopping online and procrastinating.
By Linda A. Johnson

Friday, Dec. 18, 2015

Shkreli resigns as Turing Pharmaceuticals CEO

TRENTON, N.J. - The pharmaceutical executive reviled for price-gouging resigned Friday as head of the drugmaker Turing Pharmaceuticals, a day after being arrested on charges of securities fraud.
By Linda A. Johnson

Thursday, Nov. 26, 2015

Turing won't cut its $750-per-pill price

TRENTON, N.J. - After weeks of criticism from patients, doctors and other drugmakers for raising a life-saving medicine's price more than fifty-fold, Turing Pharmaceuticals is reneging on its ...
By Linda A. Johnson

Thursday, Nov. 5, 2015

Pfizer boosts patient income limit for free drug program

TRENTON, N.J. - As the furor over soaring U.S. prescription drug prices escalates and outrageous price increases by several smaller drugmakers give the entire industry a black eye, the biggest U.S.
By Linda A. Johnson

Thursday, Oct. 29, 2015

Pfizer, Allergan in early talks

TRENTON, N.J. - Pfizer and Botox maker Allergan are discussing a potential deal that could be the biggest of 2015, a year marked by a rapid-fire pace of megadeals, particularly in health care.
By Linda A. Johnson

Wednesday, March 25, 2015

Research on rare disease drugs increases

TRENTON, N.J. - The global pharmaceutical industry is pouring billions of dollars into developing treatments for rare diseases, which once drew little interest from major drugmakers.
By Linda A. Johnson

Monday, Nov. 24, 2014

Health care M&A leads global deal surge

As drugmakers and hospitals cut costs and sharpen focus, health care deals lead global surge.
By Linda A. Johnson

Tuesday, May 6, 2014

Bayer to buy Merck's consumer care business

TRENTON, N.J. - Germany's Bayer plans to buy U.S.-based Merck & Co.'s consumer health business, creating a combined medicine cabinet from aspirin to allergy pills.
By Linda A. Johnson

Friday, April 25, 2014

Smartphone apps remind patients to take their meds

Medicine only helps if you take it properly. And adhering to an exact schedule of what to take, and when, can be challenging for patients who are forgetful or need to take several medications.
By Linda A. Johnson

Wednesday, April 2, 2014

FDA OKs tablet for seasonal allergies

TRENTON, N.J. - The Food and Drug Administration said Wednesday that it has approved the first tablet in the U.S. for gradually reducing hay fever symptoms, an alternative to months of weekly ...
By Linda A. Johnson

Monday, May 27, 2013

Valeant to buy Bausch + Lomb

Canadian drugmaker Valeant Pharmaceuticals said Monday that it will pay $8.7 billion to buy Bausch + Lomb, one of the world's best-known makers of contact lenses, in a massive expansion of ...
By Linda A. Johnson
Search Augusta jobs